-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The selection criteria for hepatectomy (HR) treatment for metaphase hepatocellular carcinoma (IM-HCC) is still controversial
The selection criteria for hepatectomy (HR) treatment for metaphase hepatocellular carcinoma (IM-HCC) is still controversial
The study divided 942 IM-HCC patients into HR group and TACE group
The study divided 942 IM-HCC patients into HR group and TACE group
A total of 942 HCC patients were enrolled, including 563 (59.
The mOS of the entire cohort was 23.
OS comparison before and after PSM
Univariate analysis found that Child-Pugh classification (vs.
Univariate analysis found that Child-Pugh classification (vs.
Univariate analysis of OS related factors
For those with a survival period of more than 6 months (HzR = 0.
For those with a survival period of more than 6 months (HzR = 0.
Comparison of OS in patients with different survival times
In the stratified analysis, the OS benefit of HR treatment was observed in patients with higher LDH levels (p = 0.
In the stratified analysis, the OS benefit of HR treatment was observed in patients with higher LDH levels (p = 0.
LDH's influence on OS LDH's influence on OS
The 1, 3, and 5-year survival rates in the TACE group were 76.
9%, 52.
7%, and 46.
7%, respectively, while the HR group was 85.
8%, 68.
6%, and 63.
3%, respectively
.
However, for patients with LDH levels <192 U/L, the 1, 3, and 5-year mortality rates of HR treatment are 2.
89 times (95% CI = 0.
71-11.
81) and 1.
20 times (95% CI = 0.
54-respectively) that of TACE treatment.
2.
65), and 1.
22 times (95% CI = 0.
57-2.
62)
.
9%, 52.
7%, and 46.
7%, respectively, while the HR group was 85.
8%, 68.
6%, and 63.
3%, respectively
.
However, for patients with LDH levels <192 U/L, the 1, 3, and 5-year mortality rates of HR treatment are 2.
89 times (95% CI = 0.
71-11.
81) and 1.
20 times (95% CI = 0.
54-respectively) that of TACE treatment.
2.
65), and 1.
22 times (95% CI = 0.
57-2.
62)
.
In summary, studies have shown that for mid-stage HCC patients with LDH>192 U/L, hepatectomy (HR) is better than TACE
.
TACE may be suitable for patients with LDH level ≤192 U/L
.
.
TACE may be suitable for patients with LDH level ≤192 U/L
.
Studies have shown that for patients with intermediate HCC with LDH>192 U/L, hepatectomy (HR) is better than TACE
.
TACE may be suitable for patients with LDH level ≤192 U/L
.
Studies have shown that for patients with intermediate HCC with LDH>192 U/L, hepatectomy (HR) is better than TACE
.
TACE may be suitable for patients with LDH level ≤192 U/L
.
Original source:
Original source:Lu L, Zheng P, Wu Z and Chen X (2021) Hepatic Resection Versus Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: A Cohort Study.
Front.
Oncol.
11:618937.
doi: 10.
3389/fonc.
2021.
618937
.
A Cohort Study Front Oncol 11:.
618937 doi:.
10.
3389 / fonc.
2021.
618937
in this message